Filing Flows › Sunshine Biopharma (SBFM) › Q4 2025
Sunshine Biopharma (SBFM) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Apr 3, 2026
Sunshine Biopharma (SBFM) reported revenue of $8.6M for the fourth quarter 2025 (Q4 2025), -11% from a year earlier and -9% from the quarter before. Operating margin was -20.9%, net loss $2.1M (25.0% of revenue).
Sunshine Biopharma, Q4 2025: revenue $8.6M (-11% year over year), operating margin -20.9%, net loss $2.1M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.6M | -9% | -11% |
| Operating profit | −$1.8M | — | — |
| Net earnings | −$2.1M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $8.6M in Q4 2025, down 11% year over year and down 9% from the previous quarter.
Gross margin was 35.3%, up 3.1 points from Q4 2024. Operating costs exceeded revenue by $1.8M, an operating margin of -20.9%. Operating expenses fell 6% while revenue fell 11%. The quarter ended with a net loss of $2.1M, wider than the previous quarter's $884K loss.
Operating cash flow was −$1.6M. Non-cash charges added back $99K of depreciation and amortization. Working capital and other items added $426K. Capital expenditures of −$1K exceeded it, leaving free cash flow of −$1.6M.
Questions
What was Sunshine Biopharma's revenue in the fourth quarter 2025?
Sunshine Biopharma (SBFM) reported revenue of $8.6M for the fourth quarter 2025 (Q4 2025), -11% from a year earlier and -9% from the quarter before.
Was Sunshine Biopharma profitable in the fourth quarter 2025?
Operating loss was $1.8M (-20.9% of revenue) and net loss $2.1M.
Source: Sunshine Biopharma 10-K on SEC EDGAR.